fda ends semaglutide shortage The Wegovy Continues, Leaving Patients On the Weight Loss Drug in Limbo Novo Nordisk's semaglutide shortage officially

Regular monitoring for pancreatitis, gallbladder disease, and bone health is important, particularly during the perimenopausal transition

VLEKT should be considered as a medical-nutritional intervention requiring a thorough clinical assessment and formal prescription by a trained healthcare professional

People with pre-existing conditions, like chronic kidney disease or heart disease, should have regular consultations to tailor the treatment plan

[8] In 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight

Fewer than 1% of tirzepatide patients in SURPASS trials discontinued due to nausea at any dose level

Pricing is transparent, with no hidden fees